Pfizer Inc. (PFE)
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should Pfizer Stock Be in Your Portfolio Post a Robust Q4 Performance?
Investors may stay invested in PFE stock to see how its new growth drivers perform.
Pfizer: Challenges Loom Amid Overvaluation
I have downgraded Pfizer Inc. stock to Strong Sell due to stagnant revenue, substantial patent cliffs, regulatory, legal, and reputational headwinds, and overvaluation concerns. Despite a 24.7% YoY revenue growth in FQ4, Pfizer's financial flexibility remains weak with significant net debt and no new products to offset patent losses. Valuation analysis indicates PFE stock is overvalued with a fair share price below $25, and consensus estimates forecast a below 2% dividend growth rate for the next two fiscal years.
Better High-Yield Dividend Stock: Pfizer vs. Merck
Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (MRK -0.88%) that offer a yield above 3%, and shares of Pfizer (PFE -0.35%) offer a yield above 6%.
Fighting Cancer Becomes Top Priority for Pfizer
Pfizer chairman and CEO Albert Bourla sees cancer as Pfizer's next big chance to save the world. The complexity of cancers makes treatments expensive to develop and challenging to customize, but the approach of making life more livable with cancer is changing the face of the disease.
Is Now a Good Time to Buy the Dip on Pfizer?
The past three years have been difficult for Pfizer (PFE -0.35%). The pharmaceutical giant's financial results worsened substantially as its coronavirus-related tailwind came to a screeching halt.
Should You Pick PFE Stock At $25?
Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per share, compared to the consensus estimates of $17.4 billion and $0.46, respectively.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Pfizer, Inc. (PFE) Q4 2024 Earnings Call Transcript
Pfizer, Inc. (NYSE:PFE ) Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ET Company Participants Francesca DeMartino - Senior Vice President, Chief Investor Relations Officer Albert Bourla - Chairman and Chief Executive Officer Dave Denton - Chief Financial Officer and Executive Vice President Chris Boshoff - Chief Scientific Officer and President of Research & Development Aamir Malik - Chief U.S. Commercial Officer and Executive Vice President Alexandre de Germay - Executive Vice President & Chief International Commercial Officer Andrew Baum - Chief Strategy & Innovation Officer and Executive Vice President Conference Call Participants Steve Scala - TD Cowen Geoff Meacham - Citibank Chris Schott - JPMorgan Vamil Divan - Guggenheim Securities Courtney Breen - Bernstein Evan Seigerman - BMO Capital Markets Kripa Devarakonda - Truist Securities Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Trung Huynh - UBS Akash Tewari - Jefferies Chris Shibutani - Goldman Sachs Alexandria Hammond - Wolfe Research Tim Anderson - Bank of America Operator Good day, everyone, and welcome to Pfizer's Fourth Quarter 2024 Earnings Conference Call. Today's call is being recorded.
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales
PFE beats fourth-quarter estimates for earnings and sales. It maintains 2025 guidance.
Pfizer's fourth quarter sales and earnings top expectations
Pfizer Inc (NYSE:PFE, ETR:PFE) posted stronger-than-expected financial results for the fourth quarter and reaffirmed its 2025 revenue guidance. The company continues to expect between $61 billion and $64 billion in revenue this year, with sales from Covid products expected to be stable year-over-year.
Compared to Estimates, Pfizer (PFE) Q4 Earnings: A Look at Key Metrics
The headline numbers for Pfizer (PFE) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
